Product image of Lidocaïne Adrenaline Aguettant (Epinephrine Bitartrate, Lidocaine Hydrochloride) supplied by GNH India

Lidocaïne Adrenaline Aguettant

Active Ingredient:
Epinephrine Bitartrate, Lidocaine Hydrochloride
Origin:
EU

Lidocaïne Adrenaline Aguettant (Epinephrine Bitartrate, Lidocaine Hydrochloride)

Lidocaine Hydrochloride and Epinephrine Bitartrate, the active ingredient in Lidocaïne Adrenaline Aguettant, is a local anesthetic presented as a sterile solution for injection for epidural, infiltration and perineural use. It provides rapid onset of numbness and prolongs the anesthetic effect for adult patients undergoing surgical or diagnostic procedures.

GNH India supplies Lidocaïne Adrenaline Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Laboratoire Aguettant

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Lidocaïne Adrenaline Aguettant, a combination local anesthetic, is employed in procedures that require regional or local anesthesia.
  • Surgical procedures: provides rapid onset anesthesia and prolongs duration for incision and excision.
  • Infiltration anesthesia: numbs targeted tissue for minor surgeries or dental work.
  • Epidural analgesia: delivers analgesia for labor or postoperative pain management.
  • Dental procedures: offers quick oral tissue numbness for extractions and restorative work.
  • Orthopedic surgery: facilitates muscle and joint anesthesia during minimally invasive interventions.
  • Cesarean section analgesia: supports epidural analgesia for labor and delivery.

How It Works

  • Lidocaine blocks voltage‑gated sodium channels on neuronal membranes, preventing depolarization and impulse propagation. Epinephrine stimulates alpha‑adrenergic receptors on vascular smooth muscle, causing vasoconstriction that reduces systemic absorption of lidocaine, prolongs its local effect, and limits bleeding at the injection site.

Side Effects

Adverse reactions may occur following administration of the combination product.

Common Side Effects

  • Transient burning or stinging at the injection site
  • Mild dizziness or light‑headedness
  • Temporary tachycardia
  • Elevated blood pressure
  • Nausea or mild vomiting
  • Localized swelling or erythema

Serious or Rare Side Effects

  • Anaphylactic or severe allergic reaction
  • Cardiac arrhythmias, including ventricular fibrillation
  • Seizures or convulsions
  • Methemoglobinemia
  • Persistent hypotension
  • Severe hypertension with reflex bradycardia

Precautions & Warnings

  • When using Lidocaïne Adrenaline Aguettant, clinicians should observe several safety measures.
  • Allergy assessment: avoid in patients with known hypersensitivity to lidocaine or epinephrine.
  • Cardiovascular status: use cautiously in individuals with uncontrolled hypertension or arrhythmias.
  • Pregnancy: evaluate risk‑benefit; limited data are available for use during pregnancy.
  • Drug interactions: review concomitant beta‑blockers, MAO inhibitors, and antiarrhythmic agents.
  • Dosage adjustment: consider reduced doses in elderly or patients with hepatic impairment.
  • Store below 25°C: keep in the original container, protect from moisture and light.

Avoid Interactions

Lidocaïne Adrenaline Aguettant may interact with several medicines; monitoring is essential.

Major Interactions (Avoid)

  • Beta‑blockers: can potentiate epinephrine‑induced hypertension and bradycardia.
  • Monoamine oxidase inhibitors (MAOIs): increase risk of hypertensive crisis with epinephrine.
  • Class I antiarrhythmics (e.g., quinidine): may enhance lidocaine toxicity.

Moderate Interactions (Monitor Closely)

  • Diuretics: may raise plasma lidocaine concentrations.
  • Tricyclic antidepressants: additive central nervous system toxicity.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase bleeding tendency due to vasoconstriction.

Frequently Asked Questions

Lidocaïne Adrenaline Aguettant is a combination of lidocaine and epinephrine used to provide rapid local anesthesia and prolong its effect for surgical, infiltration, epidural and perineural procedures in adult patients.

Lidocaine blocks voltage‑gated sodium channels, stopping nerve impulse transmission, while epinephrine activates alpha‑adrenergic receptors causing vasoconstriction. This reduces systemic absorption of lidocaine, extending the anesthetic duration and limiting bleeding at the injection site.

The dose of Lidocaïne Adrenaline Aguettant is determined by the prescribing clinician based on the specific procedure, patient characteristics, and required depth of anesthesia. Only a qualified health professional should set the dosage.

Safety data for Lidocaïne Adrenaline Aguettant in pregnancy and lactation are limited. Clinicians should weigh potential benefits against risks and consider alternative options when treating pregnant or nursing patients.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with lidocaine alone, the addition of epinephrine provides vasoconstriction, which reduces bleeding, slows systemic absorption, and prolongs the anesthetic effect. This can allow lower total lidocaine doses and longer duration of action, especially useful in procedures requiring extended anesthesia.

Lidocaïne Adrenaline Aguettant should be stored below 25 °C, in its original packaging, protected from moisture and direct light. Do not freeze the solution, and keep the vial sealed until use to maintain sterility.

The product is supplied as a sterile injectable solution and is administered by a qualified health professional via epidural, infiltration or perineural injection techniques, following aseptic procedures and appropriate dosing guidelines.

Serious risks include severe allergic reactions (anaphylaxis), cardiac arrhythmias, seizures, and methemoglobinemia. Immediate medical attention is required if any of these events occur after administration.

Patients with known hypersensitivity to lidocaine, epinephrine, or any component of the formulation should not receive this product. It should also be avoided in individuals with uncontrolled hypertension, certain cardiac conduction disorders, or those taking contraindicated interacting medications.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Epinephrine Bitartrate, Lidocaine Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT